Regulatory Briefs: FDA Plans To Study Explanted Hips, Announces Upcoming Meetings
This article was originally published in The Gray Sheet
Executive Summary
FDA is seeking applicants to help run an explant analysis study on hip implants. The agency plans a workshop on incorporating patient preference into CDRH regulatory decisions and a meeting with health professional organizations. More regulatory news.
You may also be interested in...
Regulatory Briefs: Consensus Standards; Penalty Amounts Increase; Biologics Center Seeks Branch Chief
FDA adds 53 entries to the list of standards it will recognize for device pre-market submissions, and grants de novo approval for two device types. Civil money penalty amounts increase on inflation adjustment. The Center for Biologics Evaluation and Research searches for a review branch chief. More regulatory news.
News Briefs: Boston Sci Settlement; C.R. Bard Scores Patent Victory
Boston Scientific owes another $30 million to settle more charges related to Guidant ICD issues. C.R. Bard closer to receiving big payout from Gore on patent case. FDA issues a safety alert on St. Jude’s Amplatzer occluder More news briefs.
FDA’s Final Risk-Benefit Guidance Excludes 510(k)s, Adds De Novo Petitions
Device center reviewers will begin applying the guidance to incoming PMA and de novo submissions and to submissions already under review with decisions beginning on May 1.